Two Families with Normosmic Congenital Hypogonadotropic Hypogonadism and Biallelic Mutations in KISS1R (KISS1 Receptor): Clinical Evaluation and Molecular Characterization of a Novel Mutation
Context KISS1R mutations have been reported in few patients with normosmic congenital hypogonadotropic hypogonadism (nCHH) (OMIM #146110). Objective To describe in detail nCHH patients with biallelic KISS1R mutations belonging to 2 unrelated families, and to functionally characterize a novel KISS1R mutation. Results An original mutant, p.Tyr313His, was found in the homozygous state in 3 affected kindred (2 females and 1 male) from a consanguineous Portuguese family. This mutation, located in the seventh transmembrane domain, affects a highly conserved amino acid, perturbs the conformation of the transmembrane segment, and impairs MAP kinase signaling and intracellular calcium release. In the second family, a French Caucasian male patient with nCHH was found to carry two recurrent mutations in the compound heterozygous state (p.Leu102Pro/Stop399Arg). In this man, pulsatile GnRH (Gonadotropin Releasing Hormone) administration restored pulsatile LH (Luteinizing Hormone) secretion and testicular hormone secretion. Later, long-term combined gonadotropin therapy induced spermatogenesis, enabling 3 successive pregnancies that resulted in 2 miscarriages and the birth of a healthy boy. Conclusion We show that a novel loss-of-function mutation (p.Tyr313His) in the KISS1R gene can cause familial nCHH, revealing the crucial role of this amino acid in KISS1R function. The observed restoration of gonadotropin secretion by exogenous GnRH administration further supports, in humans, the hypothalamic origin of the gonadotropin deficiency in this genetic form of nCHH.
References
[1]
Bry-Gauillard H, Trabado S, Bouligand J, Sarfati J, Francou B, et al. (2010) Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. Ann Endocrinol (Paris) 71: 158–162.
Shaw ND, Seminara SB, Welt CK, Au MG, Plummer L, et al. (2011) Expanding the phenotype and genotype of female GnRH deficiency. J Clin Endocrinol Metab 96: E566–576.
[4]
Young J (2012) Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 97: 707–718.
[5]
Mitchell AL, Dwyer A, Pitteloud N, Quinton R (2011) Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. Trends Endocrinol Metab 22: 249–258.
[6]
Noel SD, Kaiser UB (2011) G protein-coupled receptors involved in GnRH regulation: molecular insights from human disease. Mol Cell Endocrinol 346: 91–101.
[7]
de Roux N, Young J, Misrahi M, Genet R, Chanson P, et al. (1997) A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 337: 1597–1602.
[8]
Layman LC, Cohen DP, Jin M, Xie J, Li Z, et al. (1998) Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 18: 14–15.
[9]
de Roux N, Young J, Brailly-Tabard S, Misrahi M, Milgrom E, et al. (1999) The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. J Clin Endocrinol Metab 84: 567–572.
[10]
Tello JA, Newton CL, Bouligand J, Guiochon-Mantel A, Millar RP, et al. (2012) Congenital hypogonadotropic hypogonadism due to GnRH receptor mutations in three brothers reveal sites affecting conformation and coupling. PLoS One 7: e38456.
[11]
Chevrier L, Guimiot F, de Roux N (2011) GnRH receptor mutations in isolated gonadotropic deficiency. Mol Cell Endocrinol 346: 21–28.
[12]
de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, et al. (2003) Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 100: 10972–10976.
[13]
Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, et al. (2003) The GPR54 gene as a regulator of puberty. N Engl J Med 349: 1614–1627.
[14]
Lanfranco F, Gromoll J, von Eckardstein S, Herding EM, Nieschlag E, et al. (2005) Role of sequence variations of the GnRH receptor and G protein-coupled receptor 54 gene in male idiopathic hypogonadotropic hypogonadism. Eur J Endocrinol 153: 845–852.
[15]
Semple RK, Achermann JC, Ellery J, Farooqi IS, Karet FE, et al. (2005) Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 90: 1849–1855.
[16]
Pallais JC, Bo-Abbas Y, Pitteloud N, Crowley WF Jr, Seminara SB (2006) Neuroendocrine, gonadal, placental, and obstetric phenotypes in patients with IHH and mutations in the G-protein coupled receptor, GPR54. Mol Cell Endocrinol 254–255: 70–77.
[17]
Tenenbaum-Rakover Y, Commenges-Ducos M, Iovane A, Aumas C, Admoni O, et al. (2007) Neuroendocrine phenotype analysis in five patients with isolated hypogonadotropic hypogonadism due to a L102P inactivating mutation of GPR54. J Clin Endocrinol Metab 92: 1137–1144.
[18]
Teles MG, Trarbach EB, Noel SD, Guerra-Junior G, Jorge A, et al. (2010) A novel homozygous splice acceptor site mutation of KISS1R in two siblings with normosmic isolated hypogonadotropic hypogonadism. Eur J Endocrinol 163: 29–34.
[19]
Nimri R, Lebenthal Y, Lazar L, Chevrier L, Phillip M, et al. (2011) A novel loss-of-function mutation in GPR54/KISS1R leads to hypogonadotropic hypogonadism in a highly consanguineous family. J Clin Endocrinol Metab 96: E536–545.
[20]
Breuer O, Abdulhadi-Atwan M, Zeligson S, Fridman H, Renbaum P, et al. (2012) A novel severe N-terminal splice site KISS1R gene mutation causes hypogonadotropic hypogonadism but enables a normal development of neonatal external genitalia. Eur J Endocrinol 167: 209–216.
[21]
Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, et al. (2012) Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med 366: 629–635.
[22]
Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, et al. (2009) TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 41: 354–358.
[23]
Guran T, Tolhurst G, Bereket A, Rocha N, Porter K, et al. (2009) Hypogonadotropic hypogonadism due to a novel missense mutation in the first extracellular loop of the neurokinin B receptor. J Clin Endocrinol Metab 94: 3633–3639.
[24]
Young J, Bouligand J, Francou B, Raffin-Sanson ML, Gaillez S, et al. (2010) TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 95: 2287–2295.
[25]
Gianetti E, Tusset C, Noel SD, Au MG, Dwyer AA, et al. (2010) TAC3/TACR3 Mutations Reveal Preferential Activation of Gonadotropin-Releasing Hormone Release by Neurokinin B in Neonatal Life Followed by Reversal in Adulthood. J Clin Endocrinol Metab 95: 2857–2867.
[26]
Francou B, Bouligand J, Voican A, Amazit L, Trabado S, et al. (2011) Normosmic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations. PLoS One 6: e25614.
[27]
Bouligand J, Ghervan C, Tello JA, Brailly-Tabard S, Salenave S, et al. (2009) Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 360: 2742–2748.
[28]
Chan YM, de Guillebon A, Lang-Muritano M, Plummer L, Cerrato F, et al. (2009) GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A 106: 11703–11708.
[29]
Eloit C, Trotier D (1994) A new clinical olfactory test to quantify olfactory deficiencies. Rhinology 32: 57–61.
[30]
Trabado S, Maione L, Salenave S, Baron S, Galland F, et al. (2011) Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. Fertil Steril 95: 2324–2323, 2324-2329, 2329, e2321-2323.
[31]
Dode C, Levilliers J, Dupont JM, De Paepe A, Le Du N, et al. (2003) Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33: 463–465.
[32]
Dode C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, et al. (2006) Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2: e175.
[33]
Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Pinero A, et al. (2009) A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab 95: 659–669.
[34]
Eswar N, Eramian D, Webb B, Shen MY, Sali A (2008) Protein structure modeling with MODELLER. Methods Mol Biol 426: 145–159.
[35]
Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, et al. (1995) kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A 92: 7006–7010.
[36]
Jones TA, Zou JY, Cowan SW, Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47 (Pt 2) 110–119.
[37]
Lovell SC, Davis IW, Arendall III WB, de Bakker PIW, Word JM, et al.. (2002) Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins: Structure, Function & Genetics. pp. 437–450.
[38]
Clair C, Chalumeau C, Tordjmann T, Poggioli J, Erneux C, et al. (2001) Investigation of the roles of Ca(2+) and InsP(3) diffusion in the coordination of Ca(2+) signals between connected hepatocytes. J Cell Sci 114: 1999–2007.
[39]
Schmidlin F, Roosterman D, Bunnett NW (2003) The third intracellular loop and carboxyl tail of neurokinin 1 and 3 receptors determine interactions with beta-arrestins. Am J Physiol Cell Physiol 285: C945–958.
[40]
Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, et al. (2008) A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 358: 709–715.
[41]
Szereszewski JM, Pampillo M, Ahow MR, Offermanns S, Bhattacharya M, et al. (2010) GPR54 regulates ERK1/2 activity and hypothalamic gene expression in a Galpha(q/11) and beta-arrestin-dependent manner. PLoS One 5: e12964.
[42]
Goze C, Berge G, M'Kadmi C, Floquet N, Gagne D, et al. (2010) Involvement of tryptophan W276 and of two surrounding amino acid residues in the high constitutive activity of the ghrelin receptor GHS-R1a. Eur J Pharmacol 643: 153–161.
[43]
Wahab F, Quinton R, Seminara SB (2011) The kisspeptin signaling pathway and its role in human isolated GnRH deficiency. Mol Cell Endocrinol 346: 29–36.
[44]
Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M (2012) Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev 92: 1235–1316.
[45]
Ramaswamy S, Gibbs RB, Plant TM (2009) Studies of the localisation of kisspeptin within the pituitary of the rhesus monkey (Macaca mulatta) and the effect of kisspeptin on the release of non-gonadotropic pituitary hormones. J Neuroendocrinol 21: 795–804.
